Drug Type siRNA |
Synonyms PLK-1SNALP, PLK1-LNP, PLK1424 + [2] |
Target |
Action inhibitors |
Mechanism PLK1 inhibitors(Polo like kinase 1 inhibitors), RNA interference |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Hepatocellular Carcinoma | Phase 2 | United States | 01 Jun 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | China | 01 Jun 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | Canada | 01 Jun 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | Singapore | 01 Jun 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | South Korea | 01 Jun 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | Taiwan Province | 01 Jun 2014 | |
Acetyl-Coa Carboxylase Deficiency | Phase 2 | United States | 01 Dec 2010 | |
Adrenocortical Carcinoma | Phase 2 | United States | 01 Dec 2010 | |
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 01 Dec 2010 | |
Neuroendocrine Tumors | Phase 2 | United States | 01 Dec 2010 |
Phase 1 | 43 | apowpljmyg(caqyelqtqv) = trwsegwqiy txkxwyczqp (epwgtgpwsn ) View more | Negative | 01 Jun 2019 |